Enhancing the Efficacy of Cancer Vaccines in Urologic Oncology: New Directions

Overview

Journal Nat Rev Urol

Specialty Urology

Date 2009 Sep 9

PMID 19736551

Citations 10

Authors

Sergei Kusmartsev

Johannes Vieweg

Affiliations

Soon will be listed here.

Abstract

Immunotherapeutic interventions have long been utilized in urologic oncology for the treatment of metastatic renal cell or superficial transitional cell carcinoma. Most recently, the first active specific immunotherapeutic approach, a cancer vaccine, has passed the final phase of human testing and its approval by the FDA is pending. However, evidence suggests that the full protective and therapeutic potential of cancer vaccines has not yet been achieved. Through multiple mechanisms, tumors promote conditions in the tumor-bearing host that mitigate or even eliminate the vaccine-induced antitumor response. Restoration of the impaired immune function is, therefore, imperative for achieving optimum vaccine efficacy. Targeted pharmacological interventions are capable of overcoming tumor-mediated immunosuppression, and thereby enable cancer vaccination to reach its full therapeutic potential.

Citing Articles

High Levels of PD-L1 and Hyal2 Myeloid-derived Suppressor Cells in Renal Cell Carcinoma.

Kusmartsev S, Kwenda E, Dominguez-Gutierrez P, Crispen P, OMalley P J Kidney Cancer VHL. 2022; 9(2):1-6.

PMID: 35528727 PMC: 9021011. DOI: 10.15586/jkcvhl.v9i2.208.

HMGB1 promotes myeloid-derived suppressor cells and renal cell carcinoma immune escape.

Li J, Sun J, Rong R, Li L, Shang W, Song D Oncotarget. 2017; 8(38):63290-63298.

PMID: 28968989 PMC: 5609921. DOI: 10.18632/oncotarget.18796.

COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells.

Prima V, Kaliberova L, Kaliberov S, Curiel D, Kusmartsev S Proc Natl Acad Sci U S A. 2017; 114(5):1117-1122.

PMID: 28096371 PMC: 5293015. DOI: 10.1073/pnas.1612920114.

The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.

Mouraviev V, Mariados N, Albala D, Concepcion R, Shore N, Sims R Rev Urol. 2014; 16(3):122-30.

PMID: 25337042 PMC: 4191632.

Val-boroPro accelerates T cell priming via modulation of dendritic cell trafficking resulting in complete regression of established murine tumors.

Walsh M, Duncan B, Larabee S, Krauss A, Davis J, Cui Y PLoS One. 2013; 8(3):e58860.

PMID: 23554941 PMC: 3595211. DOI: 10.1371/journal.pone.0058860.

References

Katz J, Muller A, Prendergast G . Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev. 2008; 222:206-21. DOI: 10.1111/j.1600-065X.2008.00610.x. View

Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F . Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002; 8(8):831-40. DOI: 10.1038/nm731. View

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

Wang D, DuBois R . Prostaglandins and cancer. Gut. 2005; 55(1):115-22. PMC: 1856377. DOI: 10.1136/gut.2004.047100. View

Zou W . Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005; 5(4):263-74. DOI: 10.1038/nrc1586. View

Mantovani A, Allavena P, Sica A, Balkwill F . Cancer-related inflammation. Nature. 2008; 454(7203):436-44. DOI: 10.1038/nature07205. View

Christensen J . A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol. 2007; 18 Suppl 10:x3-10. DOI: 10.1093/annonc/mdm408. View

Willimsky G, Blankenstein T . Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature. 2005; 437(7055):141-6. DOI: 10.1038/nature03954. View

Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H . Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008; 14(24):8270-8. DOI: 10.1158/1078-0432.CCR-08-0165. View

10.

Gilboa E . The promise of cancer vaccines. Nat Rev Cancer. 2004; 4(5):401-11. DOI: 10.1038/nrc1359. View

11.

Hatzimouratidis K, Hatzichristou D . Looking to the future for erectile dysfunction therapies. Drugs. 2008; 68(2):231-50. DOI: 10.2165/00003495-200868020-00006. View

12.

Sinha P, Clements V, Fulton A, Ostrand-Rosenberg S . Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007; 67(9):4507-13. DOI: 10.1158/0008-5472.CAN-06-4174. View

13.

Ahn G, Brown J . Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell. 2008; 13(3):193-205. PMC: 2967441. DOI: 10.1016/j.ccr.2007.11.032. View

14.

Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W . Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006; 203(12):2691-702. PMC: 2118163. DOI: 10.1084/jem.20061104. View

15.

Rosenberg S, Yang J, Restifo N . Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004; 10(9):909-15. PMC: 1435696. DOI: 10.1038/nm1100. View

16.

Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L . Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007; 13(7):828-35. PMC: 2135607. DOI: 10.1038/nm1609. View

17.

Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J . Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol. 1999; 164(1):361-70. DOI: 10.4049/jimmunol.164.1.361. View

18.

Yang J . Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res. 2004; 10(18 Pt 2):6367S-70S. DOI: 10.1158/1078-0432.CCR-050006. View

19.

Kusmartsev S, Eruslanov E, Kubler H, Tseng T, Sakai Y, Su Z . Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol. 2008; 181(1):346-53. DOI: 10.4049/jimmunol.181.1.346. View

20.

Eruslanov E, Kaliberov S, Daurkin I, Kaliberova L, Buchsbaum D, Vieweg J . Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. J Immunol. 2009; 182(12):7548-57. DOI: 10.4049/jimmunol.0802358. View